Opus Genetics spikes on positive BEST1 trial results, Phase 3 planned for 2027
Opus Genetics reported positive 3- and 6-month results from the low-dose BIRD-1 cohort for OPGx-BEST1, with visual and structural gains and no safety issues. Regulators aligned on pivotal endpoints; Phase 3 dosing planned for 2027 after manufacturing. Addressable BEST1 market expanded to about 45,400 symptomatic patients, underpinning potentially meaningful commercial upside.
View signal analysis